Citation Impact
Citing Papers
Toxicities of chimeric antigen receptor T cells: recognition and management
2016
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Pathophysiology of Migraine: A Disorder of Sensory Processing
2017 Standout
Effective treatment of severe COVID-19 patients with tocilizumab
2020 Standout
The IL-27 p28 Subunit Binds Cytokine-Like Factor 1 to Form a Cytokine Regulating NK and T Cell Activities Requiring IL-6R for Signaling
2009
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
2014
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
2021 Standout
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
2008
Cryptochrome, Circadian Cycle, Cell Cycle Checkpoints, and Cancer
2005 StandoutNobel
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
2009
Alzheimer's β-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects
2003
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009
New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression
2010
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
2010
Osteoporosis
2019 Standout
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
2006 Standout
Rheumatoid arthritis
2009
The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
2009
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
2009
Rheumatoid arthritis
2016 Standout
Essential role of microRNA‐155 in the pathogenesis of autoimmune arthritis in mice
2011
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Defining remission in rheumatoid arthritis: Results of an initial american college of rheumatology/european league against rheumatism consensus conference
2009
Tocilizumab – A novel therapy for non-organ-specific autoimmune diseases
2012
Genetic analysis of resistance to viral infection
2007 StandoutNobel
Role of interleukin‐6 in stress, sleep, and fatigue
2012
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients
2016
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
2013
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
2015
Antiphospholipid antibodies in adults with immune thrombocytopenic purpura
2008
Trial of Tocilizumab in Giant-Cell Arteritis
2017 Standout
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
2011 Standout
Progressive arthropathy in mice with a targeted disruption of theMop3/Bmal-1 locus
2005
Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis
2015
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study
2008
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Ageing and the pathogenesis of osteoarthritis
2016
Osteoarthritis
2015 Standout
Migraine and stroke: a complex association with clinical implications
2011
Role for TNF in atherosclerosis? Lessons from autoimmune disease
2009
IL-6 as a keystone cytokine in health and disease
2015 Standout
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Intracellular Toll-like Receptors
2010 StandoutNobel
Forget personalised medicine and focus on abating disease activity
2012
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
2010 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
2016
Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis
2013 StandoutNobel
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Graves' Ophthalmopathy
2010 Standout
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
2014
Evidence that cytokines play a role in rheumatoid arthritis
2008
Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
2012
Dose-related patterns of glucocorticoid-induced side effects
2008
New complexities in helper T cell fate determination and the implications for autoimmune diseases
2008
Innate immune recognition of viral infection
2006 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis
2004
Potential Impact of Strawberries on Human Health: A Review of the Science
2004 Standout
Rheumatoid arthritis
2010 Standout
Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies
2009
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production
2009
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
2005 StandoutNobel
The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis
2010
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
2014
Association of Annular Calcification and Aortic Valve Sclerosis With Brain Findings on Magnetic Resonance Imaging in Community Dwelling Older Adults
2011
Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis
2009
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
2017
Osteoarthritis
2019 Standout
The many facets of macrophages in rheumatoid arthritis
2019
Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic review
2009
The epidemiology of glucocorticoid-associated adverse events
2008
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity
2013
Pathogen Recognition and Innate Immunity
2006 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Anemia of Chronic Disease
2005 Standout
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
2013
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
2014
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin‐6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double‐blind, placebo‐controlled trial of tocilizumab in inadequate responders to methotrexate alone
2009
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
2010
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
2011
Interleukin‐6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute‐phase reactants
2010
A systematic review of intervention thresholds based on FRAX
2016
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Interleukin‐6: a new therapeutic target in systemic sclerosis?
2013
Glucocorticoids in rheumatoid arthritis: current status and future studies
2020
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Interferon treatment of NZB mice: accelerated progression of autoimmune disease
1978
Therapeutic Targeting of the Interleukin-6 Receptor
2011
Knee osteoarthritis has doubled in prevalence since the mid-20th century
2017 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
Design, Synthesis, and Inhibitory Activity of Potent, Photoswitchable Mast Cell Activation Inhibitors
2013 StandoutNobel
Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium
2013
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus
2006 StandoutNobel
Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
2014
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
2016
Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.
1994 StandoutNobel
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
2008
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion
2016 StandoutNobel
Interleukin-6 blockade in ocular inflammatory diseases
2014
Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums
2013
Design of the Tocilizumab in Giant Cell Arteritis Trial
2013
Works of J Rovenský being referenced
Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome
2005
Non-inflammatory enthesopathies of the spine: a diagnostic approach
2000
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
2013
The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome
2005
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
2007
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
2008
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: Results of a randomized double-blind study
2007
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
2001
Prevention of spontaneous autoimmunity to DNA in NZB/Swiss mice by treatment with natural double-stranded RNA.
1975
Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome.
2005